Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENULOSE vs FLAGYL ER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lactulose is a synthetic disaccharide that is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form low molecular weight organic acids, which lower the colonic p H and increase osmotic pressure, resulting in increased stool volume and laxative effect. In hepatic encephalopathy, the acidification of the colon inhibits the growth of ammonia-producing bacteria and promotes the conversion of ammonia to ammonium ion, which is trapped in the colon and excreted, thereby reducing systemic ammonia levels.
Metronidazole, a nitroimidazole antibiotic, undergoes intracellular reduction by bacterial nitroreductases, forming cytotoxic compounds that damage DNA and inhibit nucleic acid synthesis, selectively targeting anaerobic bacteria and protozoa.
Treatment of constipation,Portal-systemic encephalopathy (including the prevention and treatment of hepatic coma)
Treatment of bacterial vaginosis (FDA-approved),Off-label: Clostridium difficile infection, anaerobic infections, trichomoniasis, amebiasis, giardiasis, rosacea, periodontal disease, Helicobacter pylori eradication
15-45 m L orally once daily, titrated to produce 2-3 soft stools per day. Maximum 60 m L per day.
750 mg orally once daily for 10 days for bacterial vaginosis.
Terminal elimination half-life is 2.1 hours in normal renal function; prolonged to up to 6 hours in renal impairment.
Terminal elimination half-life: 6-8 hours (increased to 10-12 hours with hepatic impairment; unchanged in renal impairment).
Lactulose is not metabolized in the human small intestine due to the absence of appropriate enzymes. It reaches the colon unchanged and is fermented by colonic bacteria (e.g., Lactobacillus, Bacteroides) into short-chain fatty acids (lactic acid, acetic acid, and formic acid) and gases (hydrogen, carbon dioxide).
Hepatic metabolism via side-chain oxidation and glucuronidation; metabolites are 5-nitroimidazoles and hydroxy metabolites; CYP450 enzymes (CYP2A6, CYP3A4, CYP2B6) partially involved.
Primarily renal (95% unchanged by glomerular filtration); biliary/fecal less than 5%.
Renal: 60-80% (metabolites and unchanged drug). Fecal: 6-15%. Minimal biliary.
Negligible (<1%), not bound to plasma proteins.
<20% (albumin).
Vd approximately 0.25 L/kg, primarily confined to extracellular fluid.
0.5-0.8 L/kg; indicates extensive tissue distribution including CNS.
Oral: very low (<3%) as minimally absorbed; rectal: negligible systemic absorption.
Oral: 80-95% (extended-release formulation).
No dose adjustment required for renal impairment; use with caution in severe renal impairment due to electrolyte disturbances.
No adjustment necessary for GFR >10 m L/min; for GFR <10 m L/min, consider using immediate-release metronidazole instead of FLAGYL ER due to lack of data in severe renal impairment.
No specific adjustment recommended; monitor for electrolyte imbalances in severe hepatic impairment.
Child-Pugh Class A/B: no adjustment necessary. Child-Pugh Class C: reduce dose to 375 mg orally once daily (50% of usual dose).
Infants and children: 2.5-10 m L orally once daily, adjusted to produce 2-3 soft stools per day. Maximum 40 m L per day.
Safety and efficacy not established for FLAGYL ER in pediatric patients. Use immediate-release metronidazole for pediatric dosing.
Start at lower end of dosing range (15-30 m L daily) due to increased risk of electrolyte disturbances and dehydration. Monitor serum electrolytes.
No specific dose adjustment recommended based on age alone; use caution due to potential for decreased renal function and monitor for adverse effects.
None.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. Avoid chronic use. Reserved for anaerobic and protozoal infections.
Diabetic patients should use with caution due to the sugar content. Prolonged use may lead to electrolyte disturbances (e.g., hypernatremia, hypokalemia). Use with caution in patients with galactosemia or lactose intolerance, as lactulose may contain trace amounts of lactose. Excessive dosing may cause diarrhea and fluid loss.
Peripheral neuropathy (risk with prolonged use), CNS effects (seizures, encephalopathy), disulfiram-like reaction with alcohol, sodium overload (each tablet contains 84 mg sodium), hepatic impairment may increase risk of toxicity, renal impairment (dose adjustment not typically required but monitor), superinfection including C. difficile diarrhea.
Patients with galactosemia (since lactulose contains galactose and may increase galactose levels), intestinal obstruction, or a history of hypersensitivity to lactulose or any component of the formulation.
Hypersensitivity to metronidazole or other nitroimidazoles; concurrent use of disulfiram (psychotic reactions); caution in pregnancy (first trimester only if clearly needed; crosses placenta); breastfeeding (use caution due to potential carcinogenicity).
No significant food interactions. May be mixed with fruit juice, water, or milk to mask sweet taste. Lactose-containing products may cause additional gas and bloating in lactose-intolerant patients.
Avoid alcohol and any products containing alcohol (e.g., mouthwash, cough syrups, cooking wine) during therapy and for 48 hours after last dose. No specific food restrictions otherwise.
Pregnancy Category B. No evidence of teratogenicity in animal studies; inadequate human data in first trimester. Second and third trimester: No known fetal risks associated with therapeutic doses.
Trimester 1: Crosses placenta; contraindicated in first trimester due to risk of carcinogenicity in animal studies and potential teratogenicity; use only for life-threatening infections. Trimester 2 and 3: Use with caution; associated with increased risk of cleft lip/palate in some studies; avoid if possible.
Excreted in breast milk in small amounts; M/P ratio not established. Considered compatible with breastfeeding, but monitor infant for gastrointestinal effects.
Excreted in breast milk; M/P ratio ~0.9; American Academy of Pediatrics considers compatible with breastfeeding, but advise caution; monitor infant for diarrhea or oral thrush.
No pharmacokinetic changes requiring dose adjustment during pregnancy. Standard dosing applies.
No specific dose adjustments recommended based on pregnancy pharmacokinetics; however, due to increased GFR in pregnancy, consider monitoring therapeutic levels for severe infections.
ENULOSE (lactulose) is a non-absorbable disaccharide used for constipation and hepatic encephalopathy. Monitor for electrolyte disturbances, especially hypernatremia, with prolonged use. In hepatic encephalopathy, titrate to 2-3 soft stools per day. Onset of action for constipation is 24-48 hours. Avoid in patients with galactosemia.
FLAGYL ER (metronidazole extended-release) is indicated for bacterial vaginosis. Avoid alcohol during therapy and for 48 hours after completion due to disulfiram-like reaction. Monitor for peripheral neuropathy; discontinue if signs occur. Use with caution in hepatic impairment; dose adjustment may be needed. May cause metallic taste.
Take with or without food. Mix with juice, water, or milk to improve taste.,For constipation: effect may take 24-48 hours. Do not exceed prescribed dose.,For hepatic encephalopathy: maintain 2-3 soft stools daily; adjust dose as directed.,Common side effects include bloating, gas, and cramping. These usually improve with continued use.,Contact your doctor if you experience severe diarrhea, vomiting, or signs of dehydration.,Store at room temperature, away from heat and moisture.
Take this medication exactly as prescribed; do not crush or chew the extended-release tablets.,Avoid all alcohol and alcohol-containing products during treatment and for 48 hours after the last dose to prevent severe nausea, vomiting, and flushing.,Complete the full course even if symptoms improve to ensure infection is fully treated.,Report any numbness, tingling, or pain in hands or feet to your doctor immediately.,Inform your healthcare provider if you have liver disease, a history of blood disorders, or are pregnant or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENULOSE vs FLAGYL ER, answered by our medical review team.
ENULOSE is a Laxative that works by Lactulose is a synthetic disaccharide that is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form low molecular weight organic acids, which lower the colonic p H and increase osmotic pressure, resulting in increased stool volume and laxative effect. In hepatic encephalopathy, the acidification of the colon inhibits the growth of ammonia-producing bacteria and promotes the conversion of ammonia to ammonium ion, which is trapped in the colon and excreted, thereby reducing systemic ammonia levels.. FLAGYL ER is a Nitroimidazole Antibiotic that works by Metronidazole, a nitroimidazole antibiotic, undergoes intracellular reduction by bacterial nitroreductases, forming cytotoxic compounds that damage DNA and inhibit nucleic acid synthesis, selectively targeting anaerobic bacteria and protozoa.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENULOSE and FLAGYL ER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENULOSE is: 15-45 m L orally once daily, titrated to produce 2-3 soft stools per day. Maximum 60 m L per day.. The standard adult dose of FLAGYL ER is: 750 mg orally once daily for 10 days for bacterial vaginosis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENULOSE and FLAGYL ER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENULOSE is classified as Category C. Pregnancy Category B. No evidence of teratogenicity in animal studies; inadequate human data in first trimester. Second and third trimester: No known fetal risks associated with th. FLAGYL ER is classified as Category C. Trimester 1: Crosses placenta; contraindicated in first trimester due to risk of carcinogenicity in animal studies and potential teratogenicity; use only for life-threatening infec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.